Not recruiting
Registered drug
Study on the Effects of Atacicept in Adults with IgA Nephropathy
Registered drug
Countries:
Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Atacicept
Find therapies in clinical trials near you – page 14
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
167 trials match your criteria
Not recruiting
COVID-19
Not recruitingInvestigational
Study on the Effects of S-217622 for Adults Hospitalized with COVID-19
Investigational
- Disease:COVID-19
- Substances:(6E)-6-[(6-Chloro-2-Methyl-2H-Indazol-5-Yl)Imino]-3-[(1-Methyl-1H-1,2,4-Triazol-3-Yl)Methyl]-1-[(2,4,5-Trifluorophenyl)Methyl]-1,3,5-Triazinane-2,4-Dione
Countries:Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:(6E)-6-[(6-Chloro-2-Methyl-2H-Indazol-5-Yl)Imino]-3-[(1-Methyl-1H-1,2,4-Triazol-3-Yl)Methyl]-1-[(2,4,5-Trifluorophenyl)Methyl]-1,3,5-Triazinane-2,4-Dione
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Countries:Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:Spesolimab
Countries:Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Spesolimab
Not recruiting
Dry age-related macular degeneration
Not recruitingRegistered drug
Study on JNJ-81201887 for Treating Geographic Atrophy in Age-related Macular Degeneration Patients
Registered drug
- Disease:Dry age-related macular degeneration
- Substances:PrednisoneAdeno-Associated Virus Serotype 2 Encoding Soluble Cd59+1
Countries:Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Prednisone
Not recruiting
Endometrial cancer
Not recruitingRegistered drug
Study of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy
Registered drug
- Disease:Endometrial cancer
- Substances:LoperamideNavtemadlin+2
Countries:Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Loperamide
Not recruiting
Transitional cell carcinoma
Not recruitingRegistered drugNo placebo
Study on Reduced BCG Dwell-Time for Patients with High-Risk Urothelial Cancer
Registered drugNo placebo
- Disease:Transitional cell carcinoma
- Substances:–
Countries:Denmark
Denmark- Participants:18–64 years · 65+ years
Not recruiting
Endometrial cancer
Not recruitingRegistered drug
Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery
Registered drug
- Disease:Endometrial cancer
- Substances:Anhydrous DocetaxelCarboplatin+3
Countries:Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Anhydrous Docetaxel
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study on the Effects and Safety of SAR442970 for Adults with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:Sar442970
Countries:Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Sar442970
Not recruiting
Bronchiectasis
Not recruitingRegistered drug
Study on Long-Term Safety and Efficacy of BI 1291583 in Patients with Bronchiectasis
Registered drug
- Disease:Bronchiectasis
- Substances:Bi 1291583Salbutamol Sulfate
Countries:Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Bi 1291583
Not recruiting
Mantle cell lymphoma stage II+2
Not recruitingRegistered drugNo placebo
Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma
Registered drugNo placebo
- Disease:Mantle cell lymphoma stage IIMantle cell lymphoma stage III+1
- Substances:Ibrutinib
Countries:Denmark
Denmark- Participants:18–64 years
- Substances:Ibrutinib